Sector News

Novo Nordisk's North American head Jakob Riis to leave

March 3, 2017
Life sciences

Novo Nordisk Jakob Riis FalckNovo Nordisk’s head of North America Operations and president of Novo Nordisk Inc Jakob Riis has resigned.

He will remain with the Danish pharma company for a transitional period, ahead of joining Copenhagen-based health and safety services company Falck as president and CEO on 1 May.
Riis (pictured) joined Novo in 1996 and spent 10 years as the firm’s senior vice president of global marketing, during which he took on additional responsibilities in China and the Pacific region.

However, he only held his US role for seven months, and it will now by filled by Dough Langa, who currently serves as its US senior vice president for market access.

Göran Ando, chairman of Novo’s board of directors, said: “We are of course sad to see Jakob Riis leave. He has done a great job throughout his career in Novo Nordisk, and we wish him all the best.

“We welcome Doug Langa as our new head of North America operations. Doug’s experience in the US pharmaceutical market, his leadership skills and expertise in the area of market access make him the natural successor to Jakob Riis.”

Langa joined Novo in 2011 as senior director, managed markets, from GlaxoSmithKline where he was senior director of payer marketing and prior to that spent the majority of his career at Johnson & Johnson

Source: PMLive

comments closed

Related News

May 15, 2022

Novo Nordisk and Flagship Pioneering announce a strategic collaboration to create a portfolio of transformational medicines

Life sciences

The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.

May 15, 2022

BD, Babson set sights on bringing simple blood collection into the home

Life sciences

BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.

May 15, 2022

CSL’s $11.7B Vifor buy, 2021’s biggest biopharma M&A deal, hits antitrust delay

Life sciences

Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.